Histone deacetylase inhibitors (HDACI) induce maturation, proliferation arrest and apoptosis of a wide variety of cancer cells, including leukemia, but are apparently non-toxic to normal cells. 1 Thus, several of these compounds are currently being evaluated in clinical trials, and first results are promising. Regarding acute lymphoblastic leukemia (ALL) of childhood, there is only limited in vitro data currently available regarding the proapoptotic effect of HDACI. 2, 3 Importantly, the in vivo therapeutic potential of HDACI in lymphoblastic leukemia has not yet been evaluated.
We determined the therapeutic potential of three hydroxamic acid-HDACI (Vorinostat, CBHA, Pyroxamide) and of one shortchain fatty acid-HDACI (VPA) in three B-cell precursor (BCP)-ALL cell lines (Reh, Nalm6, Z33) in vitro and in two non-obese diabetes/severe combined immunodeficiency (NOD/SCID) mouse models of childhood ALL in vivo. In vitro, all HDACI showed a dose-and time-dependent proliferation inhibition
, induction of apoptosis (annexin/propidium iodide staining, flow cytometry) and histone H4 hyperacetylation (Western blot). The calculated IC 50 (inhibitor concentration resulting in 50% non vital cells) after 96 h of HDACI incubation were in the 0-10 mM range (2-6 mM) for Vorinostat, Pyroxamide and CBHA, and in the 0.1-1 mM range (0.5-0.9 mM) for VPA (data not shown). These data are in accordance with those of others who found similar apoptosisinducing concentrations of the HDACI Vorinostat and VPA in BCP-ALL cell lines, 3, 4 suggesting that the proapoptotic effect of HDACI generally applies to BCP-ALL cell lines rather than being cell line specific. In T-cell ALL, the proapoptotic activity of several HDACI belonging to different classes (Butyrate, Trichostatin A, Vorinostat) was demonstrated previously. 2 Taken together, there is concordant evidence for the fact that HDACI are capable of inducing apoptosis in a wide variety of T-and BCP-ALL cell lines, providing a strong rationale for evaluation of these substances in preclinical models of ALL.
Therefore, we sought to determine whether HDACI treatment of NOD/SCID mice bearing ALL xenografts would have an inhibitory effect on tumor growth, as others have shown previously for xenograft mouse models of prostate cancer, neuroblastoma and acute myeloblastic leukemia. We used two NOD/SCID mouse models described in detail previously. 5, 6 Briefly, leukemic blasts emanating from long-term serial passage in NOD/SCID mice (Jackson Laboratories, Bar Harbor, MI, USA) were used, which were originally engrafted from a 1-year-old boy with first manifestation of MLL/AF4-positive BCP-ALL (subcutaneous (s.c.) model, inoculation route: small tumor fragments implanted s.c.) or from a 5-year-old girl with second relapse of BCP-ALL (intravenous (i.v.) model, inoculation route: 10 7 cells via tail vein). On treatment start (s.c. model: all mice had palpable tumors of roughly equivalent size (0.2 cm 3 70.16); i.v. model: 3 days after challenge), mice were randomly assigned to treatment groups, with eight mice in each group. Vorinostat was administered in a dose of 50, 100 or 150 mg/kg; CBHA and Pyroxamide were administered in a dose of 100 mg/ kg; and VPA was administered in two daily doses of 2 Â 200, 2 Â 250 and 2 Â 300 mg/kg. The control groups received vehicle alone. Drugs were administered via daily intraperitoneal (i.p.) injection. Animals were weighed, with dosages adjusted accordingly, and tumors were measured in two dimensions using calipers three times per week. Tumor volume was calculated using the formula: tumor volume ¼ length Â (width) 2 Â 0.5. Animals were killed by CO 2 asphyxiation when mice of the control group were moribund. Tumors and spleens were harvested for additional analysis.
The HDACI concentrations for the first series of experiments were chosen from the literature. 7, 8 For economical and ethical reasons, only substances that showed a therapeutic effect were further evaluated at higher doses.
Administration of 2 Â 200 or 2 Â 250 mg/kg/day VPA for 17 days reduced the s.c. tumor growth significantly compared with vehicle-treated controls (Po0.05; Figure 1a) . Furthermore, 100 and 150 mg/kg Vorinostat administered for 21 days caused a clear growth suppression of the xenograft tumors, the difference of which being significantly different from control animals until treatment day 14 (Po0.05; Figure 1b) . However, there was no difference between the s.c. tumor volumes of animals treated with daily 100 mg/kg Pyroxamide and CBHA, respectively, or vehicle-treated control animals (data not shown).
The treatment of mice bearing i.v.-inoculated human leukemic cells with Vorinostat (50 mg/kg/day i.p.) and VPA (2 Â 200 mg/kg/day i.p.) for 22 days reduced the spleen weight on autopsy, although the difference was borderline (VPA, P ¼ 0.093) or not significant (Vorinostat, P ¼ 0.172; Table 1) . Daily treatment with 100 mg/kg CBHA or Pyroxamide, respectively, did not result in a reduced spleen weight compared to control animals. A dose escalation of Vorinostat and VPA in the i.v. model resulted in toxicity (diarrhea, weight loss and early death) of Vorinostat (at the 100 and 150 mg/kg/day dose level) and was non-toxic for 2 Â 300 mg/kg/day VPA without additional therapeutic effect (data not shown). In the s.c. model, no apparent toxicity of the HDACI treatment was detected.
The finding that administration of 2 Â 250 mg/kg VPA and 100 or 150 mg/kg Vorinostat led to a significantly reduced s.c. tumor growth supports the hypothesis that inhibition of HDAC by VPA and Vorinostat leads to growth inhibition in BCP-ALL. This is further supported by the observation that treatment with VPA and Vorinostat was able to inhibit the leukemia-induced splenomegaly of animals after intravenous challenge with ALL blasts. CBHA and Pyroxamide did not have a growth inhibitory effect in our ALL NOD/SCID mouse models in a dose that showed a clear benefit in xenograft models of prostate cancer and neuroblastoma, respectively. 7, 8 Nevertheless, as we did not see toxicity with our dosage regimen, we cannot rule out that higher doses of CBHA and Pyroxamide could yet be effective. We observed relevant toxicity (diarrhea, weight loss and early death) at doses 100 and 150 mg/kg/day of Vorinostat in the i.v. model, but not in the s.c. model. This discrepancy could be attributed to the increased aggressiveness of i.v. model, which leads to rapidly disseminating leukemia and death, thereby resulting in a higher vulnerability of the animals to toxic side effects of the test substance. This fact has also been observed with other substances used in this i.v. model (I Fichtner, personal communication). Furthermore, at higher concentrations, Vorinostat was diluted in 45% PEG400/Aqua, as recommended by the distributing company Merck & Co., Inc. (Boston, MA, USA) (V Richon, personal communication), which may have led to an increased plasma concentration of the substance compared to saline as sole solvent. Nevertheless, results of clinical studies using oral and i.v. Vorinostat in patients with advanced malignancies showed no severe toxicity at doses where molecular (hyperacetylation of peripheral blood mononuclear cells) and clinical responses were evident.
Our data clearly demonstrate the principal efficacy of the HDACI Vorinostat and VPA in BCP-ALL of childhood, two substances already successfully used in clinical oncology. Therefore, the next step toward a future use of HDACI in childhood ALL is justified, which will encompass comprehensive combination testing in vitro and in vivo of Vorinostat and VPA with established cytostatics and also new, less toxic therapeutics in order to search for potential additive or synergistic interactions. Identifying such synergistic combinations will be an important step toward the development of effective, non-toxic therapies for children with relapsed ALL. 
